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Abstract 
Background: Testicular cancer (TC) survivors have an increased risk of various second primary malignancies. A 
recent cohort study detected an increased risk of colorectal cancer (CRC) in TC survivors treated with platinum‑based 
chemotherapy with a hazard ratio of 3.9. CRC risk increased with higher cisplatin‑dose. We know that colonoscopy 
surveillance in high‑risk populations results in reduced incidence and mortality of CRC. TC survivors treated with 
platinum‑based chemotherapy can potentially benefit from colonoscopy surveillance; however, to which extent is 
unknown. Furthermore, the pathogenesis of these secondary CRCs is unknown, and better insights into the carcino‑
genesis may affect surveillance decisions.
Methods: This prospective multicenter study will be performed in four Dutch hospitals. TC survivors are eligible if 
treated with ≥ 3 cycles of cisplatin before age 50. Colonoscopy will be performed ≥ 8 years after initial treatment 
(minimum and maximum ages at colonoscopy, 35 and 75 years, respectively). The primary aim of the study is the 
diagnostic yield of advanced neoplasia detected during colonoscopy. As secondary aim, we will evaluate the molecu‑
lar profile of advanced colorectal neoplasia and will assess current platinum levels in blood and urine and correlate 
blood‑platinum levels with prevalence of colorectal lesions. Furthermore, we will investigate effectiveness of fecal 
immunochemical testing (FIT) and burden of colonoscopy by two questionnaires. Demographic data, previous his‑
tory, results of colonoscopy, hemoglobin level of FIT and results of molecular and platinum levels will be obtained. 
Yield of colonoscopy will be determined by detection rate of adenoma and serrated lesions, advanced adenoma 
detection rate and CRC detection rate. The MISCAN model will be used for cost‑effectiveness analyses of CRC sur‑
veillance. With 234 participants undergoing colonoscopy, we can detect an absolute difference of 6% of advanced 
neoplasia with 80% power.
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Background
Due to improved treatment strategies, testicular cancer 
(TC) survival has strongly increased over the past dec-
ades, especially since the introduction of cisplatin-based 
chemotherapy [1]. As TC usually is diagnosed at a young 
age, this high cure rate results in a long life-expectancy 
[2–5]. Yet, this life-expectancy can be compromised by 
late adverse treatment effects such as second primary 
malignancies [6].
A cohort study detected an increased risk of develop-
ing colorectal cancer (CRC) in TC survivors treated with 
platinum-based chemotherapy with a hazard ratio of 
3.9 compared with the general population [7]. A dose–
response relationship between platinum and gastro-
intestinal second primary malignancies including CRC 
has been demonstrated [7]. An increased risk for gas-
tro-intestinal cancers, mainly CRC, pancreatic and gas-
tric cancer, has also been described in childhood cancer 
survivors treated with platinum-based chemotherapy 
[8]. Other studies have also reported an increased inci-
dence of CRC following TC treatment with a RR varying 
between 1.3 and 2.3 compared with the general popula-
tion [9–15]. The risk of developing CRC remained signifi-
cantly elevated for a long period after TC treatment with 
elevated risks reported even after 35  years [12, 13, 16]. 
Therefore we hypothesize that comparable to other high-
risk groups for developing CRC, colonoscopy surveil-
lance may be beneficial in the follow-up of TC survivors 
[17, 18]. Because colonoscopy is an invasive procedure, 
surveillance by fecal immunochemical testing (FIT) may 
be a good alternative. FIT is effective and a non-invasive 
CRC screening strategy, however, effectiveness in high-
risk groups is not known.
Currently, the pathogenesis of CRC in TC survivors 
exposed to cisplatin is poorly understood. In several stud-
ies, platinum was still detectable in serum and urine up 
to 20 years after treatment [19–21]. Cisplatin can cause 
DNA damage by inducing crosslinks. Therefore, CRCs 
and their precursor lesions in TC survivors may differ 
histopathologically or molecularly from sporadic CRC.
We designed a prospective study to determine the 
diagnostic yield of advanced neoplasia (advanced 
adenomas, advanced serrated lesions or CRC) in TC 
survivors treated with platinum-based chemotherapy 
as these patients have an increased risk for develop-
ing CRC. FIT surveillance is non-invasive and may be a 
good alternative to colonoscopy surveillance. The accu-
racy of FIT with regard to the detection of advanced 
neoplasia will be determined. Furthermore, the burden 
of colonoscopy and cost-effectiveness of different CRC 
surveillance strategies will be evaluated. Additionally, 
the level of platinum in plasma and urine and the his-
topathological and molecular pattern of advanced neo-
plasia will be assessed. Insight into the pathogenesis 
and the association with platinum levels may result in 
a tailored CRC surveillance program for TC survivors.
Methods/design
Objectives
The primary objective of this study is to evaluate the 
diagnostic yield of advanced colorectal neoplasia by 
surveillance colonoscopy in TC survivors treated with 
platinum-based chemotherapy. Advanced neoplasia 
is defined as advanced adenoma (high-grade dyspla-
sia, > 25% villous component or ≥ 10  mm), advanced 
serrated lesion (dysplasia or ≥ 10 mm diameter) or CRC 
[22, 23].
The secondary objectives are to assess the effective-
ness of FIT in detecting advanced neoplasia and to 
examine patient perception (burden, acceptance and 
satisfaction). We will evaluate which CRC surveillance 
strategy (FIT or colonoscopy) is most cost-effective 
in TC survivors. Furthermore, we will evaluate the 
clinicopathological and molecular characteristics of 
advanced neoplasia and relate that to platinum level in 
plasma and urine in TC survivors.
This prospective cross-sectional cohort study was 
approved by the Medical Ethics Committee of the 
Netherlands Cancer Institute (Dutch Trial Registry 
(NL68513.031.19) and registered at Clinical Trials 
(NCT04180033)) and is currently ongoing.
Discussion: TC survivors treated with cisplatin‑based chemotherapy can benefit from CRC surveillance. Evaluation 
of the diagnostic performance and patient acceptance of CRC surveillance is of importance to develop surveillance 
recommendations. Insight into the carcinogenesis of cisplatin‑related advanced colorectal lesions will contribute to 
CRC prevention in the increasing number of TC survivors. The results may also be important for the many other cancer 
survivors treated with platinum‑based chemotherapy.
Trial registration: Clinical Trials: NCT04180033, November 27, 2019, https ://clini caltr ials.gov/ct2/show/NCT04 18003 3.
Keywords: Colorectal cancer, Colorectal neoplasia, Colonoscopy, Surveillance, Testicular cancer, Platinum‑based 
chemotherapy, Surveillance, Carcinogenesis
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Study design
Population
TC survivors will be selected from a well-defined mul-
ticentre cohort including 5.848 1-year TC survivors 
who were treated between 1976 and 2007 [7]. Inclusion 
criteria for this study are as follows: (1) treatment of 
primary TC should have consisted of ≥ 3 cycles of plat-
inum-based chemotherapy consisting of cisplatin; (2) 
diagnosis of TC was made before the age of 50  years; 
(3) initial treatment for TC administered at least 8 years 
prior to inclusion; (4) the patients should be at least 
35 years of age and not older than 75 years of age and 
(5) detection and potential treatment of advanced colo-
rectal neoplasia should be considered beneficial, i.e. 
life-expectancy of at least 5 years.
TC survivors are not eligible for participation in this 
study if they meet one of the following exclusion cri-
teria: a history of proctocolectomy, colonoscopy sur-
veillance for other indications (including hereditary 
CRC syndrome, familial CRC syndrome, inflamma-
tory bowel disease, history of colorectal adenoma or 
CRC), colonoscopy in the past 3  years, ongoing cyto-
toxic treatment or radiotherapy for malignant disease, 
coagulopathy (prothrombin time < 50% of control; 
partial tromboplastin time > 50  s) or anticoagulants 
(fenprocoumon, acenocoumarol, or direct oral antico-
agulants) or platelet aggregation inhibitors that cannot 
be stopped or safely bridged if necessary, comorbidity 
leading to an impaired physical performance (World 
health organization (WHO) performance status 3–4) or 
mental retardation, limited Dutch language skills or no 
informed consent.
A total of 1.801 men treated in the four different hos-
pitals in the Netherlands could potentially be eligible. 
Individuals who do meet the inclusion criteria will be 
invited for participation in one of the four Dutch study 
centers (Netherlands Cancer Institute, Amsterdam, 
Erasmus University Medical Center, Rotterdam, Rad-
boud University Medical Center, Nijmegen and Univer-
sity Medical Center Utrecht, Utrecht). The flowchart of 
the design of this study is shown in Fig.  1. Participants 
who are eligible for participation will be invited for this 
study. Referral to the gastroenterology department will 
occur via the general practitioner or medical oncologist, 
depending whether the individual is still in follow-up for 
TC. Informed consent will be concluded by a gastroen-
terologist or nurse specialist, when the participant was 
informed adequately.
For patients who will be excluded due to colonoscopy 
in the 3 years prior to invitation we will evaluate the yield 
of colonoscopy retrospectively. This study was approved 
by the Institutional Review Board of the Netherlands 
Cancer Institute (IRBd19-236).
Control population
The diagnostic yield of colonoscopy in TC survivors will 
be compared to the NordICC study. This is a European 
randomized trial for population-based primary colonos-
copy screening for colorectal cancer. Participants were 
between 55 and 64  years of age and we selected only 
male participants to compare with our male cohort of TC 
survivors [24]. For molecular profiling, data will be com-
pared with existing molecular data of colorectal lesions 
(mainly polyps) diagnosed in Dutch patients before the 
age of 70 years [25].
Sample size calculation
The power calculation is based on the primary endpoint 
of this study: the diagnostic yield of advanced colorec-
tal neoplasia by screening colonoscopy. The prevalence 
of advanced colorectal neoplasia in the NordICC study 
population was 10.3% among the 6,493 male partici-
pants who underwent colonoscopy screening (based on 
the most recent data) [24]. We will use the data from the 
male participants of the NordICC study aged 55–64 years 
old and use frequency matching with 5-year strata of 
the NorcICC male patients to patients in our study. 
We do believe that colonoscopy surveillance is justi-
fied with an increase detection rate of advanced neo-
plasia adjusted for age of 6%. In order to detect this 6% 
Men selected out of TC cohort (n = 1.801)
Check in- and exclusion criteria 
Invitation of eligible TC survivors





Informed consent and intake for colonoscopy
Blood and urine sample, FIT, questionnaire 1
Colonoscopy (including biopsies of normal colonic
mucosa)
Questionnaire 2
Appointment for results colonoscopy + follow-up
Fig. 1 Flowchart of study. Abbreviations: FIT Fecal immunochemical 
test; TC testicular cancer
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difference in advanced neoplasia in TC survivors with 
at least 80% power (using a two-sided alpha of 5%), we 
need to include at least 234 TC survivors. A margin of 
40% will be considered for non-responders and drop-outs 
based on previous participation rates and therefore 338 
men will be approached. An interim analysis will be per-
formed after the inclusion of 100 participants.
Study procedures
Colonoscopy
The bowel preparation will be performed as for routine 
colonoscopy by ingesting a commonly prescribed oral 
electrolyte lavage solution. Conscious sedation (with 
midazolam and/or fentanyl citrate or propofol) and car-
diopulmonary monitoring will be used according to 
standard protocol. The colonoscopy will be performed 
by experienced gastroenterologists having performed 
at least 1000 colonoscopies or under direct supervision 
of an experienced gastroenterologist. When colorectal 
neoplasia is detected, polypectomy will be performed 
or biopsies will be obtained according to standard pro-
tocol. In case of a polyp ≥ 10 mm, four field biopsies will 
be taken around the polyp. Additional fresh frozen mate-
rial of non-neoplastic mucosa will be taken for study 
purposes from all participants to perform additional 
molecular analyses (see section histology, immunohis-
tochemistry and molecular pathology). Four biopsies of 
normal mucosa (fresh frozen) of the transverse colon and 
two to four biopsies of normal mucosa of the descending 
colon (fresh frozen) will be taken.
Histology, immunochemistry and molecular pathology
An experienced gastro-intestinal pathologist will per-
form routine histopathological evaluation of colorectal 
neoplasia. All advanced neoplasia will be requested from 
all four hospitals and will be re-evaluated by the same 
pathologist (PS) and.immunohistochemical and molecu-
lar analysis will be performed on these advanced lesions. 
Immunohistochemistry (IHC) of the MMR proteins 
(MLH1/MSH2/MSH6 and PMS2) will be performed and 
DNA will be isolated. A mutational panel (Sequenom 
Massarray including AKT1, BRAF, DDR2, EGFR, MEK1, 
PIK2CA, KRAS and NRAS) will be executed. The definite 
analyses will be based on an ongoing retrospective study 
on CRC in TC survivors.
Biopsies
Biopsies of normal colorectal tissue from the transverse 
and descending colon will be obtained after informed 
consent, as previously described. This fresh frozen tis-
sue will be evaluated to further understand the effect of 
platinum-based chemotherapy on endoscopically normal 
mucosa.
Questionnaires
The participant will receive a first questionnaire together 
with the information about the colonoscopy after 
informed consent is given, before colonoscopy is per-
formed. This questionnaire will evaluate risk factors for 
CRC risk (including familial history), quality of life, the 
physical and mental functioning of the patient and the 
expected burden of colonoscopy. A second question-
naire will be sent to the participant one week after the 
colonoscopy. This questionnaire will again assess quality 
of life, the physical and mental functioning of the patient 
and will determine the experienced burden of colonos-
copy. The questionnaires will include information on the 
expected/experienced burden, embarrassment and pain 
of the bowel preparation and the colonoscopy procedure.
Fecal immunochemical test
Patients will receive instructions and the stool test (FIT, 
FOBgold test) after informed consent. Prior to bowel 
preparation for the surveillance colonoscopy, patients are 
asked to collect a stool sample to perform FIT and send 
the stool kit to the laboratory for processing and analy-
sis. The FIT is a quantitative test and the level of hemo-
globin will be detected in µg Hb/g feces. The sensitivity, 
specificity, positive predictive value, negative predictive 
value and area under the curve can be calculated for 
(advanced) neoplasia with the colonoscopy of the partici-
pant as a reference.
Platinum in plasma and urine
We will measure the platinum level in a single plasma 
(6 mL EDTA containing tube) and a urine sample using 
inductively coupled plasma mass spectrometry (ICP-
MS). A blood and urine sample will be collected on the 
day of intake or before the colonoscopy. ICP-MS will be 
performed according to a protocol previously described 
[19, 26, 27].
Cost‑effectiveness analysis
Cost-effectiveness analysis of colonoscopy surveillance 
will be evaluated using the microsimulation screening 
analysis (MISCAN) model [28, 29]. In this model, the 
influence of the implementation of a surveillance pro-
gram (colonoscopy or FIT) will be simulated. This model 
can estimate the incidence, prevalence and mortality of 
CRC, and the results and effects of surveillance based 
on the prevalence of advanced neoplasia detected dur-
ing this current study and taking to account the mortal-
ity risk of TC survivors [30]. The costs and number of 
life-years gained for the population with and without the 
implementation of surveillance will be evaluated. Based 
on these results, we can make recommendations for CRC 
surveillance based on the most cost-effective strategy.
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Discussion
In this prospective study, TC survivors treated with 
platinum-based chemotherapy will be offered a colonos-
copy in order to evaluate the diagnostic yield in detecting 
advanced neoplasia as we hypothesize that this popula-
tion benefits from CRC surveillance. This study is cur-
rently ongoing and we expect to complete inclusion in 
June 2022.
Colonoscopy reduces the risk of CRC and CRC related 
mortality [31–33]. CRC screening programs for the gen-
eral average-risk population have been implemented in 
many countries [24, 34]. There are different CRC screen-
ing modalities including primary colonoscopy screening 
and fecal occult blood test screening with colonoscopy 
in case of a positive test result. For high-risk-groups a 
more intensified surveillance program is recommended, 
and the interval used differs between the different high-
risk-groups [18, 35]. For individuals with a family history 
of CRC and an estimated increased risk of CRC of 2.5 
compared to the general population, colonoscopy sur-
veillance is advised every 5 years from the age of 45 years 
[17, 18]. During colonoscopy precursor lesions of CRC 
can directly be removed which has been shown to 
reduce CRC incidence and mortality in high-risk-groups 
[31, 36–39]. TC survivors treated with platinum-based 
chemotherapy do have a 3.9-fold increased risk. Due to 
the increased CRC risk, we will evaluate the diagnostic 
yield of colonoscopy surveillance. The diagnostic yield of 
advanced neoplasia detected during colonoscopy in TC 
survivors will be compared to the male population of the 
NordICC study, which contains males with an average 
risk for developing CRC [24].
The participation rate of CRC surveillance is of great 
importance to benefit as many TC survivors as pos-
sible. Currently, most TC survivors are unaware of the 
increased risk of developing CRC. In a Dutch pilot study 
with primary colonoscopy screening the participation 
rate of colonoscopy was only 21% [34]. On the other 
hand, colonoscopy participation in a high risk group of 
familial risk was reported between 40% [40]. Therefore, 
FIT surveillance should be considered, as FIT is less inva-
sive than colonoscopy and therefore could increase the 
participation rate in CRC surveillance. There are already 
studies showing that FIT surveillance may be beneficial 
in different risk groups for CRC by choosing a low cut-
off [41]. However, in familial colorectal cancer and other 
patients with an increased risk of CRC, the accuracy of 
FIT is unknown.
In high-risk-groups for developing CRC, colonos-
copy surveillance has been shown to be cost-effective 
[42, 43]. The MISCAN model will be adapted by spe-
cific CRC risk data and competing mortality risk data 
of TC survivors. We will than evaluate the CEA of both 
colonoscopy and FIT screening at different cut-off lev-
els. This will result in an advise for further surveillance 
in TC survivors.
We hypothesize that the carcinogenesis of (the pre-
cursor lesions of ) CRC in TC survivors treated with 
platinum-based chemotherapy differs from sporadic 
CRC. It is known that cisplatin can induce cytotoxic-
ity through the formation of DNA crosslinks due to 
covalent bonds between purines [44–51]. The analysis 
which will be performed on the tissue obtained from 
this study will depend on an ongoing retrospective 
study where the histopathological and molecular char-
acteristics of CRC diagnosed in TC survivors treated 
with platinum-based chemotherapy will be evaluated 
(data not yet published).
Finally, level of platinum in plasma will be determined 
in order to see if there is correlation between the level of 
platinum in plasma and the presence of (advanced) neo-
plasia detected during the colonoscopy. It is unknown 
whether persisting retention of platinum adducts in 
plasma correlate with the increased risk of advanced neo-
plasia [19, 20]. Furthermore, urine platinum level will be 
evaluated as cisplatin is renally excreted, and was also 
detected 17  years after platinum treatment [7]. Maybe 
platinum levels in plasma and urine may guide indication 
for colonoscopy surveillance.
This protocol describes a prospective cross-sectional 
cohort study where we will evaluate the diagnostic yield 
of advanced neoplasia in TC survivors treated with 
platinum-based chemotherapy. Furthermore, we will 
evaluate the effectiveness of FIT, patient acceptance and 
burden of colonoscopy and also the most cost-effective 
CRC surveillance strategy. Additionally, we aim to gain 
insights into the pathogenesis of CRC in TC survivors 
which includes determining platinum levels in plasma 
and urine. Through this study we aim to provide CRC 
surveillance recommendations. This knowledge may 
also be of guidance for other cancer survivors who have 
received platinum-based chemotherapy for other types of 
malignancies.
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